Library / Repair / Cartalax
Cartilage / fibroblast bioregulator
Cartalax
Bioregulator
ClassKhavinson peptide
Typical routes in papersOral in that tradition
Half-life contextShort
EvidenceRussian bioregulator literature
What it is
Cartalax is marketed toward cartilage and connective-tissue aging — joints, skin matrix, fibroblasts.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Plain-language hope: happier joints and connective tissue with age.
- It lives next to BPC/TB-500 in storefronts, but the evidence style is different (short oral bioregulators vs injectable repair peptides).
- Keep expectations in the “traditional supplement-like course” bucket.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Proposed regulation of fibroblast / cartilage gene expression.
Possible side effects / caveats
Under-studied by FDA-drug standards.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited courses | 1–2 mg class | Cycled oral | Tradition |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.